LUC00140I1 - - Google Patents
Info
- Publication number
- LUC00140I1 LUC00140I1 LUC00140C LUC00140I1 LU C00140 I1 LUC00140 I1 LU C00140I1 LU C00140 C LUC00140 C LU C00140C LU C00140 I1 LUC00140 I1 LU C00140I1
- Authority
- LU
- Luxembourg
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8668708P | 2008-08-06 | 2008-08-06 | |
| US15103609P | 2009-02-09 | 2009-02-09 | |
| US17308809P | 2009-04-27 | 2009-04-27 | |
| PCT/US2009/051879 WO2010017055A2 (fr) | 2008-08-06 | 2009-07-27 | Inhibiteurs de poly(adp-ribose)polymérase (parp) de type dihydropyridophtalazinone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LUC00140I1 true LUC00140I1 (fr) | 2019-12-13 |
| LUC00140I2 LUC00140I2 (fr) | 2021-02-12 |
Family
ID=41129519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00140C LUC00140I2 (fr) | 2008-08-06 | 2019-12-11 |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8012976B2 (fr) |
| EP (3) | EP2326650B9 (fr) |
| JP (3) | JP5984389B2 (fr) |
| KR (1) | KR101846029B1 (fr) |
| CN (3) | CN102171214B (fr) |
| AR (1) | AR072970A1 (fr) |
| AU (1) | AU2009279944B2 (fr) |
| BR (1) | BRPI0917119B1 (fr) |
| CA (1) | CA2732797C (fr) |
| CY (3) | CY1115022T1 (fr) |
| DK (2) | DK2767537T3 (fr) |
| ES (2) | ES2625817T3 (fr) |
| FR (1) | FR19C1071I2 (fr) |
| GB (1) | GB2462361A (fr) |
| HK (2) | HK1157755A1 (fr) |
| HR (1) | HRP20170982T1 (fr) |
| HU (2) | HUE035295T2 (fr) |
| IL (1) | IL211070A (fr) |
| LT (2) | LT2767537T (fr) |
| LU (1) | LUC00140I2 (fr) |
| MX (1) | MX2011001328A (fr) |
| NL (1) | NL301021I2 (fr) |
| NO (1) | NO2019042I1 (fr) |
| NZ (1) | NZ591166A (fr) |
| PL (2) | PL2767537T3 (fr) |
| PT (2) | PT2326650E (fr) |
| SG (2) | SG10201809895YA (fr) |
| SI (2) | SI2767537T1 (fr) |
| TW (2) | TW201422617A (fr) |
| WO (1) | WO2010017055A2 (fr) |
| ZA (1) | ZA201100897B (fr) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5984389B2 (ja) | 2008-08-06 | 2016-09-06 | ビオマリン プハルマセウトイカル インコーポレイテッド | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
| AU2009327357C1 (en) | 2008-12-19 | 2017-02-02 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of ATR kinase |
| AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
| US20110190266A1 (en) * | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| PL2533640T3 (pl) * | 2010-02-08 | 2017-06-30 | Medivation Technologies, Inc. | Sposób syntezy pochodnych dihydropirydoftalazynonu |
| WO2011130661A1 (fr) * | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp) |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| RU2598606C3 (ru) * | 2010-10-21 | 2021-12-20 | МЕДИВЭЙШН ТЕКНОЛОДЖИЗ ЭлЭлСи | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она |
| WO2012166151A1 (fr) * | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml) |
| WO2013028495A1 (fr) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
| EP3733185B1 (fr) | 2011-09-30 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Traitement du cancer du poumon non à petites cellules avec des inhibiteurs de l'atr |
| HUE046429T2 (hu) | 2011-09-30 | 2020-03-30 | Vertex Pharma | ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás |
| CN106083849A (zh) * | 2011-12-31 | 2016-11-09 | 百济神州有限公司 | 作为parp抑制剂的稠合的四元或五元环吡啶并酞嗪酮类化合物 |
| LT2797921T (lt) | 2011-12-31 | 2017-11-27 | Beigene, Ltd. | Kondensuoti tetra arba penta-cikliniai dihidrodiazepino karbazolonai, kaip parp inhibitoriai |
| MX367614B (es) | 2012-01-20 | 2019-08-28 | Del Mar Pharmaceuticals | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. |
| US20140044802A1 (en) | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| JP6223995B2 (ja) | 2012-11-08 | 2017-11-01 | 日本化薬株式会社 | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 |
| WO2014164767A1 (fr) | 2013-03-13 | 2014-10-09 | Forma Therapeutics, Inc. | Nouveaux composés et nouvelles compositions pour inhiber fasn |
| CA2938626A1 (fr) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions permettant d'ameliorer l'avantage therapeutique du bisantrene |
| TW201605814A (zh) * | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
| WO2015154064A2 (fr) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Utilisation de dianhydrogalactitol et de leurs analogues ou dérivés dans le traitement du carcinome non à petites cellules des poumons et du cancer des ovaires |
| PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
| CN107155326B (zh) | 2014-07-31 | 2021-03-05 | 麦迪韦逊科技有限公司 | 一种共形成体盐及其制备方法 |
| WO2016138574A1 (fr) | 2015-03-02 | 2016-09-09 | Sinai Health System | Facteurs de recombinaison homologue |
| WO2017003723A1 (fr) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et leurs utilisations |
| CN107922425B (zh) | 2015-08-25 | 2021-06-01 | 百济神州有限公司 | 制备parp抑制剂、结晶形式的方法及其用途 |
| WO2017059357A1 (fr) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr |
| US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
| WO2018059437A1 (fr) * | 2016-09-27 | 2018-04-05 | Beigene, Ltd. | Traitement de cancers à l'aide d'une combinaison comprenant des inhibiteurs de parp |
| JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
| CN108210461A (zh) * | 2016-12-16 | 2018-06-29 | 中国科学院上海药物研究所 | 一种Talazoparib药物组合物及其应用 |
| CN107556312B (zh) * | 2016-12-29 | 2020-04-10 | 广州丹康医药生物有限公司 | 具有parp抑制活性的新型稠环化合物、其制备方法和用途 |
| CN107573341B (zh) * | 2016-12-29 | 2020-08-14 | 广州丹康医药生物有限公司 | 作为parp抑制剂的新型稠环化合物、其制备方法和应用 |
| WO2018122168A1 (fr) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinaisons d'inhibiteurs de kinase bub1 et d'inhibiteurs de parp |
| CN115433187B (zh) | 2017-02-28 | 2023-10-27 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 |
| CN110650961B (zh) * | 2017-05-08 | 2022-09-27 | 广州丹康医药生物有限公司 | Parp抑制剂、其药物组合物、制备方法和应用 |
| WO2019023278A1 (fr) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | Modulateurs de la somatostatine et utilisations de ces derniers |
| US20200254091A1 (en) | 2017-10-13 | 2020-08-13 | Merck Patent Gmbh | Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| CN110272419A (zh) * | 2018-03-14 | 2019-09-24 | 上海艾力斯医药科技有限公司 | 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 |
| CN108341792B (zh) * | 2018-04-28 | 2021-09-17 | 苏州莱克施德药业有限公司 | 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法 |
| CN108676888B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种肺部恶性肿瘤易感性预测试剂盒及系统 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| WO2020092395A1 (fr) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | Formes solides de (4-(2-fluoro-4-(1-méthyl-1h-benzo[d]imidazol-5-yl)benzoyl)pipérazin-1-yl)(1-hydroxycyclopropyl)méthanone |
| WO2020095184A1 (fr) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinaisons pour le traitement du cancer |
| EP3969450B1 (fr) | 2019-05-14 | 2023-10-25 | Suzhou Four Health Pharmaceuticals Co., Ltd | Dérivés de quinazoline-2,4-dione utilisés en tant qu'inhibiteurs de parp |
| US11826430B2 (en) | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2021097046A1 (fr) | 2019-11-13 | 2021-05-20 | Nuvation Bio Inc. | Composés ciblant des récepteurs hormonaux nucléaires anticancéreux |
| CN111116514B (zh) * | 2020-01-10 | 2024-03-19 | 广州科锐特生物科技有限公司 | 一种1-环丙甲酰基哌嗪盐酸盐的制备方法 |
| CA3174908A1 (fr) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Proteines de fusion et leurs utilisations |
| AU2021379314A1 (en) | 2020-11-13 | 2023-06-15 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
| CA3203814A1 (fr) | 2020-12-07 | 2022-06-16 | Pfizer Inc. | Procedes d'identification d'une tumeur sensible au traitement par le talazoparib et procedes de traitement associes |
| CA3214408A1 (fr) | 2021-03-23 | 2022-09-29 | Nuvation Bio Inc. | Composes ciblant des recepteurs hormonaux nucleaires anticancereux |
| CA3214316A1 (fr) | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combinaison de talazoparib et d'un anti-androgene pour le traitement du cancer de la prostate metastatique sensible a la castration et mute par le gene ddr |
| US20240279225A1 (en) * | 2021-04-08 | 2024-08-22 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| EP4334314A1 (fr) | 2021-05-03 | 2024-03-13 | Nuvation Bio Inc. | Composés ciblant des récepteurs hormonaux nucléaires anticancéreux |
| EP4089093A1 (fr) * | 2021-05-12 | 2022-11-16 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Radiosynthèse de [18f] talazoparib |
| WO2023131894A1 (fr) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Perte d'hétérozygotie génomique en tant que biomarqueur prédictif pour le traitement par le talazoparib et méthodes de traitement de cette perte d'hétérozygotie génomique |
| WO2023201338A1 (fr) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de parp |
| WO2023233295A1 (fr) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Dérivés de thiadiazolyle utilisés en tant qu'inhibiteurs d'adn polymérase thêta et leurs utilisations |
| WO2023239789A1 (fr) * | 2022-06-08 | 2023-12-14 | Valo Health, Inc. | Inhibiteurs de parp de phtalazinone tricyclique et procédés d'utilisation |
| CN115572218B (zh) * | 2022-08-29 | 2024-04-16 | 江阴勒森生物科技有限公司 | 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法 |
| TW202425975A (zh) | 2022-10-02 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| CN116283924B (zh) * | 2023-01-16 | 2024-07-26 | 四川效佳科技有限公司 | 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US106631A (en) * | 1870-08-23 | Improvement in seed-planter | ||
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) * | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| DE69521002T3 (de) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens |
| ES2164136T5 (es) | 1994-08-12 | 2009-02-16 | The University Of Utah Research Foundation | Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q. |
| GB9505538D0 (en) * | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| EP1077946A1 (fr) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Composes condenses tricycliques inhibant l'activite de type poly(adp-ribose) polymerase (parp) |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) * | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| PL372171A1 (en) | 2002-02-19 | 2005-07-11 | Ono Pharmaceutical Co, Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| EP1340819A1 (fr) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Marqueurs de microsatellites |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (fr) * | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase |
| CA2505876A1 (fr) | 2002-11-12 | 2004-05-27 | Mochida Pharmaceutical Co., Ltd. | Nouveaux inhibiteurs de parp |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| US7268138B2 (en) | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| WO2005080356A1 (fr) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Composes de tetrazole et leur utilisation comme antagonistes de recepteurs de glutamate metabotropiques |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| CA2684105C (fr) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Derives de la pyridine |
| AU2007358076A1 (en) | 2007-08-22 | 2009-02-26 | 4Sc Ag | Indolopyridines as inhibitors of the kinesin spindle protein (Eg5 ) |
| KR101596526B1 (ko) * | 2007-10-03 | 2016-02-22 | 에이자이 아이엔씨. | Ｐａｒｐ 억제제 화합물, 조성물 및 사용 방법 |
| EP2247600A4 (fr) | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | Inhibiteurs à base de composés benzoxazole-carboxamide de l activité poly(adp-ribose)polymérase (parp) |
| JP5984389B2 (ja) | 2008-08-06 | 2016-09-06 | ビオマリン プハルマセウトイカル インコーポレイテッド | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤 |
| KR20110053424A (ko) | 2008-08-12 | 2011-05-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 사이클로알킬-치환된 피페라진 화합물의 제조 방법 |
| AU2011212928B2 (en) | 2010-02-03 | 2016-06-23 | Medivation Technologies Llc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| PL2533640T3 (pl) | 2010-02-08 | 2017-06-30 | Medivation Technologies, Inc. | Sposób syntezy pochodnych dihydropirydoftalazynonu |
| WO2011130661A1 (fr) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Méthodes d'utilisation d'inhibiteurs dihydropyridophthalazinoniques de la poly(adp-ribose) polymérase (parp) |
| WO2011140009A1 (fr) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Procédés d'utilisation de glycopeptides semi-synthétiques en tant qu'agents antibactériens |
| RU2598606C3 (ru) | 2010-10-21 | 2021-12-20 | МЕДИВЭЙШН ТЕКНОЛОДЖИЗ ЭлЭлСи | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она |
| WO2012166151A1 (fr) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Utilisation d'inhibiteurs de dihydropyridophtalazinone de poly(adp-ribose) polymérase (parp) dans le traitement d'un syndrome myélodysplasique (mds) et d'une leucémie myéloïde aiguë (aml) |
| WO2013028495A1 (fr) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| TW201605814A (zh) | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| CN107155326B (zh) | 2014-07-31 | 2021-03-05 | 麦迪韦逊科技有限公司 | 一种共形成体盐及其制备方法 |
-
2009
- 2009-07-27 JP JP2011522113A patent/JP5984389B2/ja active Active
- 2009-07-27 SI SI200931668T patent/SI2767537T1/sl unknown
- 2009-07-27 BR BRPI0917119-3A patent/BRPI0917119B1/pt active IP Right Grant
- 2009-07-27 EP EP09805360.6A patent/EP2326650B9/fr active Active
- 2009-07-27 PT PT98053606T patent/PT2326650E/pt unknown
- 2009-07-27 SG SG10201809895YA patent/SG10201809895YA/en unknown
- 2009-07-27 US US12/510,096 patent/US8012976B2/en active Active
- 2009-07-27 PT PT141546648T patent/PT2767537T/pt unknown
- 2009-07-27 CN CN200980139634.2A patent/CN102171214B/zh active Active
- 2009-07-27 ES ES14154664.8T patent/ES2625817T3/es active Active
- 2009-07-27 MX MX2011001328A patent/MX2011001328A/es active IP Right Grant
- 2009-07-27 WO PCT/US2009/051879 patent/WO2010017055A2/fr active Application Filing
- 2009-07-27 SG SG2013065719A patent/SG193842A1/en unknown
- 2009-07-27 CN CN201410640197.5A patent/CN104478875B/zh active Active
- 2009-07-27 CA CA2732797A patent/CA2732797C/fr active Active
- 2009-07-27 PL PL14154664T patent/PL2767537T3/pl unknown
- 2009-07-27 NZ NZ591166A patent/NZ591166A/xx unknown
- 2009-07-27 DK DK14154664.8T patent/DK2767537T3/da active
- 2009-07-27 LT LTEP14154664.8T patent/LT2767537T/lt unknown
- 2009-07-27 AU AU2009279944A patent/AU2009279944B2/en active Active
- 2009-07-27 ES ES09805360.6T patent/ES2466565T3/es active Active
- 2009-07-27 SI SI200930881T patent/SI2326650T1/sl unknown
- 2009-07-27 EP EP17161893.7A patent/EP3241832A1/fr not_active Withdrawn
- 2009-07-27 CN CN201410003342.9A patent/CN103896942A/zh active Pending
- 2009-07-27 DK DK09805360.6T patent/DK2326650T3/en active
- 2009-07-27 PL PL09805360T patent/PL2326650T3/pl unknown
- 2009-07-27 KR KR1020117005152A patent/KR101846029B1/ko active IP Right Grant
- 2009-07-27 HU HUE14154664A patent/HUE035295T2/en unknown
- 2009-07-27 EP EP14154664.8A patent/EP2767537B1/fr active Active
- 2009-08-04 GB GB0913474A patent/GB2462361A/en not_active Withdrawn
- 2009-08-05 TW TW103106940A patent/TW201422617A/zh unknown
- 2009-08-05 AR ARP090102999A patent/AR072970A1/es active IP Right Grant
- 2009-08-05 TW TW098126400A patent/TWI448464B/zh active
-
2011
- 2011-02-03 ZA ZA2011/00897A patent/ZA201100897B/en unknown
- 2011-02-03 IL IL211070A patent/IL211070A/en active Protection Beyond IP Right Term
- 2011-03-31 US US13/077,785 patent/US8420650B2/en active Active
- 2011-11-04 HK HK11111926.3A patent/HK1157755A1/xx unknown
-
2013
- 2013-03-06 US US13/787,496 patent/US8999987B2/en active Active
-
2014
- 2014-03-28 CY CY20141100240T patent/CY1115022T1/el unknown
-
2015
- 2015-02-03 HK HK15101138.4A patent/HK1200813A1/xx unknown
- 2015-02-26 US US14/632,825 patent/US9820985B2/en active Active
- 2015-04-30 JP JP2015093417A patent/JP2015157843A/ja active Pending
-
2017
- 2017-05-31 CY CY20171100578T patent/CY1119218T1/el unknown
- 2017-06-29 HR HRP20170982TT patent/HRP20170982T1/hr unknown
- 2017-07-27 JP JP2017145036A patent/JP2018012698A/ja active Pending
- 2017-09-28 US US15/719,534 patent/US10543209B2/en active Active
-
2019
- 2019-11-28 NO NO2019042C patent/NO2019042I1/no unknown
- 2019-11-28 CY CY2019044C patent/CY2019044I2/el unknown
- 2019-12-03 FR FR19C1071C patent/FR19C1071I2/fr active Active
- 2019-12-05 LT LTPA2019522C patent/LTC2767537I2/lt unknown
- 2019-12-11 NL NL301021C patent/NL301021I2/nl unknown
- 2019-12-11 LU LU00140C patent/LUC00140I2/fr unknown
- 2019-12-13 US US16/714,474 patent/US10780088B2/en active Active
- 2019-12-19 HU HUS1900053C patent/HUS1900053I1/hu unknown
-
2020
- 2020-08-21 US US17/000,271 patent/US11364241B2/en active Active